These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29805983)

  • 21. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
    Keshelava N; Groshen S; Reynolds CP
    Cancer Chemother Pharmacol; 2000; 45(1):1-8. PubMed ID: 10647494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells.
    Koh J; Lee SB; Park H; Lee HJ; Cho NH; Kim J
    Biochem Biophys Res Commun; 2012 Oct; 427(2):373-8. PubMed ID: 22995296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.
    Di Matteo S; Bilotta MT; Pelosi A; Haas D; Theinert T; Weber G; Schlegel PG; Berg M; Moretta L; Maggi E; Azzarone B; Vacca P; Tumino N; Caruana I
    Front Immunol; 2024; 15():1382931. PubMed ID: 38736882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells.
    McNerney KO; Karageorgos SA; Hogarty MD; Bassiri H
    Front Immunol; 2020; 11():873. PubMed ID: 32457760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma.
    Lindskog M; Spenger C; Jarvet J; Gräslund A; Kogner P
    J Natl Cancer Inst; 2004 Oct; 96(19):1457-66. PubMed ID: 15467035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice.
    Castriconi R; Dondero A; Cilli M; Ognio E; Pezzolo A; De Giovanni B; Gambini C; Pistoia V; Moretta L; Moretta A; Corrias MV
    Cancer Immunol Immunother; 2007 Nov; 56(11):1733-42. PubMed ID: 17426969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of Neuroblastoma NK-Cell-Mediated Lysis through NF-kB p65 Subunit-Induced Expression of FAS and PVR, the Loss of Which Is Associated with Poor Patient Outcome.
    Brandetti E; Focaccetti C; Pezzolo A; Ognibene M; Folgiero V; Cotugno N; Benvenuto M; Palma P; Manzari V; Rossi P; Fruci D; Bei R; Cifaldi L
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
    Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
    Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells.
    Shoae-Hassani A; Hamidieh AA; Behfar M; Mohseni R; Mortazavi-Tabatabaei SA; Asgharzadeh S
    J Immunother; 2017 Sep; 40(7):265-276. PubMed ID: 28622272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of IFNγ and chemotherapeutic agents increase TRAIL sensitivity of neuroblastoma cell lines.
    Tong HX; Lu CW; Wang QS; Ma LY
    Eur J Pediatr Surg; 2011 Oct; 21(5):304-9. PubMed ID: 21751122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity.
    Castriconi R; Dondero A; Negri F; Bellora F; Nozza P; Carnemolla B; Raso A; Moretta L; Moretta A; Bottino C
    Eur J Immunol; 2007 Nov; 37(11):3190-6. PubMed ID: 17918205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
    Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A
    Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.
    Liu L; Li Y; Xiong X; Qi K; Zhang C; Fang J; Guo H
    Int J Oncol; 2016 Dec; 49(6):2319-2330. PubMed ID: 27840903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
    Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
    Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.
    Zingoni A; Cecere F; Vulpis E; Fionda C; Molfetta R; Soriani A; Petrucci MT; Ricciardi MR; Fuerst D; Amendola MG; Mytilineos J; Cerboni C; Paolini R; Cippitelli M; Santoni A
    J Immunol; 2015 Jul; 195(2):736-48. PubMed ID: 26071561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Signaling from p53 to NF-kappaB determines the chemotherapy responsiveness of neuroblastoma.
    Armstrong MB; Bian X; Liu Y; Subramanian C; Ratanaproeksa AB; Shao F; Yu VC; Kwok RP; Opipari AW; Castle VP
    Neoplasia; 2006 Nov; 8(11):967-77. PubMed ID: 17132229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells.
    Schilling D; Kühnel A; Tetzlaff F; Konrad S; Multhoff G
    Cancer Immunol Immunother; 2015 May; 64(5):599-608. PubMed ID: 25854583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
    Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
    Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.